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Abstract
To inform the development of interventions to increase uptake and adherence to antiretroviral therapy (ART), we explored 
perceptions of ART in semi-structured interviews with 52 men and women from UK black African and black Caribbean 
communities. Verbatim transcripts were analyzed using framework analysis. Perceptions of ART could be grouped into 
two categories: doubts about the personal necessity for ART and concerns about potential adverse effects. Doubts about 
necessity stemmed from feeling well, doubts about the efficacy of ART, religious beliefs and the belief that treatment was 
futile because it could not cure HIV. Concerns about adverse effects included the fear that attending HIV services and taking 
treatment would lead to disclosure of HIV, feeling overwhelmed at the prospect of starting treatment soon after diagnosis, 
fears about side effects and potential long-term effects, and physical repulsion. The findings will facilitate the development 
of interventions to increase uptake and adherence to ART.
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Introduction
Effective antiretroviral therapy (ART) has dramatically 
reduced morbidity and mortality associated with HIV infec-
tion [1] and can prevent transmission to sexual partners 
[2]. Good adherence to effective treatment should not only 
improve physical health, but also psychological wellbeing by 
empowering patients to take an active role in managing their 
condition [3]. Modelling studies have shown that if sufficient 
numbers of people living with HIV (PLWH) are diagnosed 
and take sustained and effective treatment, new HIV infec-
tions could be eradicated within the next two decades [4]. 
In 2014, the Joint United Nations Programme on HIV/AIDS 
(UNAIDS) proposed a target of ending the AIDS epidemic 
by 2030 [4]. The report set out three milestones that would 
need to be achieved by 2020 in order to reach this target: (1) 
90% of all people with HIV knowing their HIV status; (2) 
90% PLWH who know their diagnosis receiving continuous 
treatment and (3) 90% of people with diagnosed HIV having 
viral suppression [4].
At the end of 2017, globally 75% of PLWH knew their 
status, 79% of those who knew their diagnosis were on treat-
ment and 81% of those on treatment had viral suppression 
[5]. In the UK, the UNAIDS targets had been met [6, 7]. 
Despite these successes, delay to treatment uptake and poor 
adherence to medication continue to pose important chal-
lenges. The number of people with diagnosed HIV who were 
not taking ART was likely to be an underestimate because 
not everyone who is prescribed ART actually receives or 
takes it [8]. Furthermore, although nonadherence is a com-
mon cause of treatment failure, it is not synonymous with 
undetectable viral load. Several studies show that nonad-
herence to ART remains suboptimal: a meta-analysis of 84 
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studies across 20 different countries found the mean rate of 
ART adherence (defined as ≥ 90%) was 62% [9]. Since rates 
of adherence tend to decline over time [10], it is important 
that barriers to adherence are addressed before viral load 
becomes detectable.
There is a comprehensive literature on factors influencing 
adherence to ART. In common with most behaviors, adher-
ence is a product of motivation and ability [11]. In order 
to optimize ART uptake and adherence, there is a need to 
understand why people with HIV may not want or be able 
to initiate and continue to take ART. One approach is to 
consider the perceptions (e.g. beliefs about HIV and ART) 
that may influence motivation together with the practicali-
ties (e.g. capability and resources) influencing the ability 
to adhere.
The beliefs influencing uptake and adherence can be con-
ceptualized by the Necessity Concerns Framework (NCF). 
Studies across the UK and the USA show that beliefs about 
personal necessity for ART and concerns about potential 
adverse effects predict delay to uptake and nonadherence 
[10, 12–15]. These studies used the Beliefs about Medicines 
Questionnaire (BMQ), a valid and reliable method of quanti-
fying adherence related beliefs (Necessity Beliefs and Con-
cerns) using items identified in qualitative studies [16, 17]. 
While previous studies have found that the NCF is relevant 
in minority ethnic groups [13] it is not clear whether the 
items in the BMQ capture all of the salient issues in people 
from black African and black Caribbean communities in 
the UK. Lower rates of engagement with treatment and care 
have been observed within these communities when com-
pared to the overall UK population of people living with 
HIV [18, 19].
Factors influencing engagement with HIV care have pre-
viously been identified in studies conducted in Africa and 
the Caribbean, as well as with people from black African 
communities living in the UK. A recent systematic review 
(n = 59) of studies reporting on factors influencing decision-
making among PLWH in Africa identified three groups of 
challenges: (1) those associated with poverty, stigma and 
unpredictable life events, (2) challenges relating to the health 
care system, and (3) self-efficacy and social, financial and 
practical support [20]. A systematic review of studies con-
ducted in Latin America and the Caribbean (n = 53) identi-
fied several barriers to adherence to ART among PLWH in 
the Caribbean [21], including perceptions of HIV providers, 
alcohol use, a lack of social support for adherence, having 
children and experiences of side effects [21].
Studies conducted with people from black African com-
munities living in the UK have identified several barriers 
to accessing healthcare services including HIV-associated 
stigma, fear of discrimination, the perception that access-
ing healthcare was unnecessary in the absence of symptoms 
and competing priorities (such as housing and employment 
issues) [22]. Fewer studies have identified barriers to ART 
uptake and adherence. A study conducted 20 years ago 
identified several concerns about ART among black Afri-
can PLWH living in London including concerns about short 
and long-term side effects, lack of confidence in ART, dis-
trust of the medical profession and fears of discrimination 
[23]. One study found lower attendance in care among black 
African PLWH who believed that only God can cure HIV; 
however, religiousness (e.g. attendance at religious services 
and religious beliefs) was not associated with initiation of 
ART or subsequent changes in viral load [24]. The quality 
of doctor-patient relationships may be an important deter-
minant of adherence to ART: in a study of African migrants 
in London, some participants felt that their concerns about 
side effects had not been taken seriously, and had stopped 
treatment as a result [25].
Given the lack of current research focusing on perceptual 
barriers to ART uptake and adherence among black African 
and black Caribbean PLWH in the UK, the aim of this study 
was to identify the salient perceptual barriers to ART uptake 
and adherence in a sample of people of black African and 
black Caribbean descent living with HIV in London.
Methods
This was a cross-sectional, qualitative, interview-based 
study. Qualitative methodologies are optimal to examine 
participants’ views and experiences [26].
Sampling
Study participants were recruited from specialist HIV out-
patient clinics at Homerton University Hospital and King’s 
College Hospital in London, UK. Patients were eligible if 
they were ≥ 18 years, had a diagnosis of HIV, were of black 
African or Caribbean ethnicity, were born in Africa or the 
Caribbean, had been prescribed ART for ≥ 12 months and 
were assessed by clinicians as being nonadherent to ART 
according to 2012 British HIV Association (BHIVA) guide-
lines [27]. Purposive sampling was used to reflect a broad 
range of geographical provenance and stage of HIV infection 
(asymptomatic vs symptomatic) (Table 1).
Recruitment
Potential participants were informed about the study by their 
HIV clinicians and introduced to study researchers during 
routine visits. Consistent with the main study aim, patients 
were told that the purpose of the study was to understand 
their perceptions and experiences of ART. Written informed 
consent was obtained. Approval for this study was granted 
by the City and East London Research Ethics Committee 
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(11/LO/0970). Participants were reimbursed £20 for their 
time and expenses.
Data Collection
Data were collected through in-depth, individual face-to-
face interviews conducted in clinical settings by experi-
enced qualitative researchers (EG, JSp). Interview guides 
were semi-structured, consisting of open-ended questions 
and prompts to explore participants’ experiences of ART, 
including what taking treatment meant to the participant 
and its importance in their life, how they took treatment, 
and whether they had concerns about taking ART (and con-
versely not taking it). Demographic characteristics were 
obtained by a self-report questionnaire.
Data Analysis
An independent service transcribed each recording verbatim, 
which was then reviewed for quality by the Researcher who 
conducted the interview (EG or JSp). Data were analyzed 
using framework analysis [28]. This method was chosen 
because it allows for the inductive exploration of patients’ 
accounts while also enabling the exploration of pre-defined 
theory [28]. Our analysis was guided by the Necessity Con-
cerns Framework [16]. Each transcript was read whilst lis-
tening to the recording. Two researchers (EG and JSp) ini-
tially developed a framework of key issues and themes. This 
framework was used to code a further subset of interviews 
and was refined through discussion. A comprehensive data 
chart was then constructed by extracting segments of data 
from the transcripts and arranging these in a matrix accord-
ing to emerging themes. The corpus of extracts was managed 
using NVivo 10.0.
Results
Fifty-two patients of West African (n = 23), East African 
(n = 17), Central/South African (n = 2) and Caribbean 
(n = 10) heritage were interviewed between February and 
August 2012. Interviews were conducted in English (50) 
and French [2]. Ten themes were identified. These themes 
could be grouped under two main categories: five themes 
were categorized as doubts about the necessity for treatment 
and five were categorized as concerns about adverse effects 
(Table 2).
Doubts About the Necessity for ART 
No Symptoms, No Problem
The rationale for taking ART was sometimes unclear to peo-
ple who were not experiencing specific symptoms that they 
associated with HIV. These participants described taking 
treatment as being at odds with their idea of the purpose of 
medication, which was to alleviate symptoms, rather than as 
a strategy to prevent them from becoming ill. Many people 
found it difficult to accept the need for ART when they were 
feeling fine.
Table 1  Sample characteristics (n = 52)
a Symptomatic status was determined with the US Centers for Disease 
Control and Prevention (CDC) classification system: Stage A: free 
from clinical symptoms such as opportunistic infections; CDC stage 
B or C: experiencing symptomatic conditions that are attributed to 
HIV, indicate a defect in cell mediated immunity are complicated by 
HIV infection or the presence of an AIDS-indicator condition
Demographic or clinical characteristic
Gender
 Female n (%) 35 (60)
Age
 Years Median (IQR) 44 (37–49)
Region of birth
 West Africa n (%) 23 (44)
 East Africa n (%) 17 (33)
 Other Africa n (%) 2 (4)
 Caribbean n (%) 10 (19)
Employment
 Professional n (%) 8 (15)
 Manual n (%) 5 (10)
 Unemployed n (%) 37 (71)
 Student n (%) 2 (4)
Symptomatic  statusa
 Symptomatic n (%) 28 (53)
 Asymptomatic n (%) 24 (46)
Years since HIV diagnosis Median (IQR) 9 (3–12)
Years since treatment start Median (IQR) 6 (3–9)
Table 2  Perceptions of ART identified in framework analysis
Doubts about the necessity for ART 
 No symptoms, no problem
 Fatalistic beliefs
 Beliefs linked to stigma and shame
 Conflict regarding the roles of God and medicine
 Doubts about effectiveness
Concerns about ART 
 Insufficient time to address concerns
 Risk of disclosure of HIV through ART 
 Decreased quality of life from side effects
 Physical repulsion
 Concerns about long-term effects
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If you have a headache you say let me take paraceta-
mol to make [it] stop. And you’re told you have HIV, 
but you don’t have symptoms, you are not sick from 
it and you are told “take medication”. I don’t have 
headache and they are giving me medication to stop 
the headache. (Female (F), 40, Zimbabwean, symp-
tomatic, 16 years since diagnosis).
Fatalistic Beliefs About HIV
Many participants initially believed that they would die 
from HIV. For some, this belief was based on previous 
experiences, such as experiencing a family member’s 
death from AIDS-related illness. Some participants felt 
that because HIV is incurable, they would die from it, and 
therefore there was no point to taking medication. Taking 
medicine each day to control HIV did not fit with these 
participants’ perception of HIV as a fatal illness.
It’s an incurable disease, you’re going to die. It’s like 
having a death sentence hanging over you and the 
shock, the despair… it does affect the taking of the 
medication because you think at the end of the day 
what’s the use, what’s the point of using it, because 
you’re going to die. It’s not curable. (M, 47, Zam-
bian, symptomatic, 10 years since diagnosis)
Beliefs Linked to Stigma and Shame
Participants frequently described having experienced feel-
ings of shame and self-blame after being diagnosed HIV 
positive. For some participants, the sense of shame felt 
about being HIV-positive was so great that they did not 
want to take treatment to live.
HIV is a punishment… So I cannot live my life… 
I thought maybe, I was hoping, I was going to die 
quickly. (M, 54, Zambian, symptomatic, 12 years 
since diagnosis)
Others did not accept that their diagnosis of HIV was 
correct, considering that the diagnosis must have been 
made in error or attributing symptoms or test results to 
another condition. In this context, it did not make sense to 
participants to take ART.
I am still having doubt [about the diagnosis] until 
it is proven right…. If it’s a mistake somewhere I 
think the earlier we can identify it the better. Some-
thing else can be wrong with my blood… It might be 
something new or modern. (Male (M), 45, Ivorian, 
symptomatic, 2 years since diagnosis)
Conflict Regarding the Roles of God and Medicine
Some participants had a strong conviction that HIV could be 
cured by their belief in God. This was strengthened by witness-
ing testimonies in church from parishioners who claimed that 
they were no longer HIV positive following sufficient prayer. 
A participant recounted that a parishioner showed a letter from 
their doctor stating that they were cured of their HIV. For these 
participants, being healed was a measure of one’s strength as 
a believer. Remaining HIV positive was interpreted by some 
as an indication of inadequate belief in God on their part to be 
able to receive a cure.
You might see someone who has had the same sickness 
for 40 years, and he still hasn’t been healed, and then 
you will see someone who has just suffered 2 years and 
miraculously he will be healed. It’s all about faith. That 
is what I believe, that it all depends on faith. (M, 47, 
Zambian, symptomatic, 11 years since diagnosis)
For some participants, there was an internal conflict regard-
ing the role of God and ART in the treatment of HIV. Although 
they expressed the resolute belief that only faith would prevent 
them from becoming ill, this was inconsistent with the fact that 
they were taking at least some of their treatment.
Doubts About Effectiveness
Doubts about the effectiveness of ART stemmed from par-
ticipants’ common-sense beliefs about their medicines, which 
were often at odds with the medical rationale for treatment. For 
example, some participants perceived that ART would not be 
necessary if they were able to boost their immune system in 
a more organic way, e.g. by eating healthily or taking natural 
remedies. Some participants had misconceptions about their 
treatment, for example the belief that efficacy was associ-
ated with the number of tablets they were prescribed. This is 
illustrated by the following quote, where the participant was 
concerned that her current one-tablet regimen would be less 
effective than the 4-tablet regimen she had taken previously:
This new one you only take it once a day, are they reduc-
ing it down because I’m taking [ART for] too long? I 
wonder if I’m going to [be] dead soon because they’re 
reducing it down (F, 38, Ugandan, asymptomatic, 
2 years since diagnosis)
Concerns About ART 
Insufficient Time to Come to Terms with an HIV Diagnosis 
Before Starting ART 
The majority of participants had been diagnosed with HIV 
at a late stage of infection and had been recommended to 
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start ART immediately. Many participants were devastated 
and overwhelmed by their diagnosis and found it difficult to 
both come to terms with being HIV-positive and commit to 
life-long treatment at the same time. In this context, partici-
pants described having difficulty taking in the information 
they were given. There was insufficient time for them to 
articulate their concerns about ART to their doctor, meaning 
they started treatment with strong concerns about taking it.
At first they will just be talking to you and everything 
is just going in other ways. You’ll just be sitting and 
they are talking to you but when you leave they’ll 
know everything’s gone. Yes, just passing through into 
your ears and out on top of your head. (F, 41, Ugandan, 
symptomatic, 2 years since diagnosis)
Risk of Disclosure of HIV Through ART 
Many people explained that if other people in their commu-
nities became aware of their HIV status, they risked severe 
social and economic consequences. This was particularly 
true for people who were dependent on small networks of 
support, those who faced immigration restrictions, or who 
were staying with friends or acquaintances and who faced 
the risk of ostracism or homelessness if people knew that 
they were living with HIV. Some participants had concerns 
about attending the HIV clinic, in case they recognized 
members of their community, or taking treatment, in case 
the physical characteristics of the medication, such as large 
or colorful tablets attracted attention, making their HIV sta-
tus visible.
I don’t have a house, so I was sleeping with friends… 
I can’t take the medication because maybe they will 
start talking about me and maybe they would refuse 
me sleeping in their house. (F, 37, Nigerian, asympto-
matic, 2 years since diagnosis)
Decreased Quality of Life from Side Effects
Many participants experienced side effects from their ART 
and associated taking treatment with feeling ill. Taking ART 
was perceived by some to have reduced rather than increased 
their quality of life. This was especially true for participants 
who had not been experiencing symptoms that they asso-
ciated with HIV before initiating treatment. For some, the 
experience of taking ART was so adverse that the promise of 
longer-term health was not enough to outweigh the negative 
experience of taking medication.
I don’t see what they’re doing for me, all they’re doing 
they’re just making me feel worse. (F, 35, Jamaican, 
asymptomatic, 4 years since diagnosis)
Physical Repulsion
Many patients talked about the physical attributes of the 
tablets themselves. Some reported difficulty in swallowing, 
while others found the taste and size of the tablets off-putting 
or nausea-inducing. These barriers led participants to view 
ART as an impediment in their lives and at times even a 
source of repulsion.
I just want to throw up. Sometimes I throw up and 
think, good, it’s out of my body now. (M, 32, Guya-
nese, 4 years since diagnosis)
Concerns About Long Term Effects
Concerns about long-term effects of ART were common. 
Many patients feared that ART was toxic and were con-
vinced it would cause damage to their body in the long-term, 
a situation which they perceived as no better than letting 
HIV take its course. For some patients, negative experiences 
of ART such as side effects tipped the balance in favor of 
nonadherence as the preferable health strategy.
I was saying you are trying to get me better but at the 
same time you’re killing me. (F, 52, Jamaican, asymp-
tomatic, 3 years since diagnosis).
Discussion
This study identified perceptual barriers to ART in people of 
African and Caribbean heritage living in the UK. Consistent 
with studies conducted across long-term conditions [29], 
these barriers could be grouped into two categories—doubts 
about the necessity for ART and concerns about adverse 
effects. The findings are consistent with an extended com-
mon-sense model of self-regulation [11], which proposes 
that although the behaviors that patients adopt to cope with 
their illness are often at odds with medical advice, they 
make sense when viewed in the light of patients’ beliefs 
about their illness and treatment. Understanding patients’ 
common-sense perspectives of their condition and treatment 
is an important first step in the development of strategies to 
increase adherence.
Five of the beliefs identified represented doubts about 
the necessity for ART. The perception that treatment is not 
necessary in the absence of symptoms and a preference for 
non-pharmacological methods of controlling HIV were con-
sistent with those identified in a previous study conducted 
with men who have sex with men (MSM) who declined a 
clinically indicated recommendation to initiate ART [17]. 
The belief that faith in God can cure HIV was previously 
identified in a study of newly diagnosed black African men 
and women receiving treatment for HIV in London, where 
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over a third of frequent church attenders believed that HIV 
could be cured by faith in God [24]. Other beliefs identified 
in the current study which may influence patients’ percep-
tions of their personal necessity for ART include patients’ 
doubts about the validity of their HIV diagnosis and a fatal-
istic view of HIV as an incurable, untreatable disease.
Five of the themes identified in this study related to 
patients’ concerns about ART. In common with previous 
studies [10, 14, 17], many patients had concerns about side 
effects, potential long-term effects due to toxicity and a 
physical repulsion to ART. Fears of discrimination leading 
to the need to conceal one’s HIV status from others have 
been previously documented among people from black Afri-
can communities in Europe [30–32], and HIV stigma has 
been associated with lower adherence [33]. An additional 
concern identified in this study was a lack of time between 
the diagnosis of HIV and the recommendation to initiate 
ART. Many people reported being overwhelmed by their 
simultaneous diagnosis of HIV and committing to life-long 
treatment. In this context, patients felt that they did not 
have sufficient time to articulate their concerns about ART 
before initiating treatment. This is an important considera-
tion given that late diagnosis (CD4 count < 350 cells/mm3) 
is common among people from black African and black 
Caribbean communities in the UK [27, 34] meaning that 
a significant proportion of people in these populations are 
recommended immediate initiation of ART. Importantly, UK 
and international HIV treatment guidelines now recommend 
that patients should start ART as soon as possible after diag-
nosis, regardless of their CD4 count, so prescribing practices 
will need to consider the patient’s preparedness to ensure a 
successful treatment initiation [1]. Evidence that people who 
have strong concerns about ART at the time of a treatment 
recommendation are more likely to decline treatment or to 
be nonadherent 12 months later highlights the need to elicit 
and address concerns about ART at this stage of the care 
pathway [10]. PLWH in this study described being unable to 
take in or recall the information that they were given in this 
context, demonstrating the need for tailored interventions 
and support with appropriate information resources.
These findings show the importance of understanding 
patients’ beliefs about HIV and ART in order to ensure that 
the rationale for ART can be communicated in a way that 
makes sense to the individual and which does not conflict 
with their existing beliefs. Most of the themes identified 
in this study are present in the Beliefs about Medicines 
Questionnaire (BMQ-ART) [10, 16], which can be used to 
elicit beliefs about ART. Cognitive behavioral techniques 
may be useful to explore and challenge unhelpful or inac-
curate beliefs. Patients’ doubts about their personal neces-
sity for ART may be addressed by presenting the medical 
rationale for ART in a way that addresses or aligns with a 
patient’s common sense view. Concerns about side effects 
may be addressed during consultations by routinely discuss-
ing unwanted effects that they may be experiencing, pro-
viding relevant pharmaceutical treatment and advice that 
is tailored and appropriate to the individual. Fears about 
potential unwanted and adverse effects may be addressed by 
exploring the potential benefits of ART with the patient and 
weighing this up against the likelihood of short and long-
term unwanted effects. In this study, many patients were 
concerned that their HIV status would be revealed to others 
by the conspicuously large size and vivid color of their ART 
tablets. It is possible that generic medicines, which are less 
distinguishable in their appearance, may help address these 
concerns.
The findings of this study should be interpreted in the 
light of its limitations. This was a cross sectional study and 
although patients were asked about different points in their 
treatment journey, they were not followed over time, there-
fore we were unable to determine which beliefs were more 
prevalent at each timepoint (diagnosis, recommendation of 
treatment and ongoing adherence). While it is possible that 
some patients may not have been forthcoming in disclos-
ing nonadherence, the range of beliefs elicited suggests that 
patients felt able to discuss the issues pertinent to them. 
The use of qualitative methods was appropriate to examine 
beliefs about ART in previously under-researched groups, 
however it was not possible to determine the strength the 
beliefs identified using this approach. Further studies using 
quantitative methods are required to determine how strongly 
these beliefs are held and whether they differ between cul-
tural groups. Since the interviews were conducted there 
have been significant developments in research and treat-
ment which may impact on patients’ beliefs about ART 
and treatment decisions. Following robust evidence that 
individuals with an undetectable viral load on ART are not 
able to transmit HIV to others [2] a test and treat approach 
where all people diagnosed with HIV are recommended to 
start ART as soon as possible has been adopted [35]. This 
has led to initiatives to help individuals to initiate ART as 
close as possible to receiving their diagnosis. Furthermore, 
since these interviews were conducted there has been the 
development of newer fixed dose, single tablet regimens, 
and generic medicines consisting of smaller, more discreet 
pills tablets which may reduce concerns about disclosure of 
HIV through ART.
Conclusions
In order to increase uptake and adherence to ART, the 
National Institute for Clinical Excellence (NICE) recom-
mends eliciting and addressing both perceptual and practi-
cal barriers to treatment. This study has identified percep-
tual barriers to ART in previously under-researched UK 
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populations and may therefore be useful in clinical practice 
and for those developing evidence-based interventions to 
support uptake and adherence to ART. The findings will 
inform the development of an intervention to increase indi-
vidual motivation to initiate ART and maintain a high level 
of adherence over the long-term, in order to optimize physi-
cal and psychological outcomes for people living with HIV 
and help to achieve and maintain the targets set by UNAIDS.
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